J Rheum Dis.  2021 Jan;28(1):38-44. 10.4078/jrd.2021.28.1.38.

Treatment Response to Idiopathic Retroperitoneal Fibrosis-associated Hydronephrosis With a Focus on IgG4/IgG3 Serum Concentration Ratio

• Choi SJ
• Oh JS
• Hong S
• Lee CK
• Yoo B
• Hong B
• Kim YG

• KMID: 2510341
• DOI: http://doi.org/10.4078/jrd.2021.28.1.38

Abstract

Objective
. Hydronephrosis, a common complication of idiopathic retroperitoneal fibrosis (iRPF), may lead to poor renal outcomes unless resolved in a timely manner. IgG4-related diseases characterized by elevated serum IgG4 levels are responsible for a few iRPF cases. However, the underlying immunologic features of most iRPF cases have not been clearly defined, and these cases exhibit varied responses to medical treatment. Thus, we investigated the predictive factors for hydronephrosis-associated outcomes among iRPF patients.
Methods
. We retrospectively included 18 iRPF patients with hydronephrosis in a tertiary referral hospital from 2012 to 2019. Hydronephrosis improvement was assessed on images taken 6 months after diagnosis. Categorical variables were compared using chi-square or Fisher’s exact test. Continuous variables were compared using Mann–Whitney U-test.
Results
. On follow-up images, 8 patients (44.4%) showed an improvement in hydronephrosis. Patients with improvement more frequently had reverse serum IgG4/IgG3 ratio (87.5% vs. 30%, p=0.025), abdominal aorta involvement (87.5% vs. 30%, p=0.025) and glucocorticoid treatment administration (87.5% vs. 30%, p=0.025) than those without improvement. The proportion of elevated serum IgG4 level did not differ between the two groups. Even in the 14 cases with normal serum IgG4 levels, reverse serum IgG4/IgG3 ratio was more frequently observed in patients with improvement than in those without improvement (83.3% vs. 12.5%, p=0.026).
Conclusion
. The reverse serum IgG4/IgG3 ratio was associated with hydronephrosis improvement in iRPF patients, suggesting it to be a suitable serologic marker for predicting favourable responses to glucocorticoid treatment.

Keyword

Immunoglobulins; Retroperitoneal fibrosis; Hydronephrosis; Glucocorticoids

Reference

1. Vaglio A, Salvarani C, Buzio C. 2006; Retroperitoneal fibrosis. Lancet. 367:241–51. DOI: 10.1016/S0140-6736(06)68035-5. PMID: 16427494.

2. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, et al. 1987; Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol. 60:497–503. DOI: 10.1111/j.1464-410X.1987.tb05028.x. PMID: 3427331.

3. Vaglio A, Maritati F. 2016; Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 27:1880–9. DOI: 10.1681/ASN.2015101110. PMID: 26860343. PMCID: PMC4926988.

4. Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. 2013; Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 92:82–91. DOI: 10.1097/MD.0b013e318289610f. PMID: 23429355. PMCID: PMC4553983.

5. Magrey MN, Husni ME, Kushner I, Calabrese LH. 2009; Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. 61:674–9. DOI: 10.1002/art.24461. PMID: 19404998.

6. Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF. 2012; Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. 27:2819–25. DOI: 10.1093/ndt/gfr779. PMID: 22273666.

7. Zhao J, Li J, Zhang Z. 2019; Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study. Scand J Rheumatol. 48:239–45. DOI: 10.1080/03009742.2018.1497700. PMID: 30270709.

8. Forestier A, Buob D, Mirault T, Puech P, Gnemmi V, Launay D, et al. 2018; No specific imaging pattern can help differentiate IgG4-related disease from idiopathic retroperitoneal fibrosis: 18 histologically proven cases. Clin Exp Rheumatol. 36:371–5. PMID: 29465374.

9. Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. 2020; The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 79:77–87. DOI: 10.1136/annrheumdis-2019-216561. PMID: 31796497.

10. Xia CS, Fan CH, Liu YY. 2017; Diagnostic performances of serum IgG4 concentration and IgG4/IgG ratio in IgG4-related disease. Clin Rheumatol. 36:2769–74. DOI: 10.1007/s10067-017-3685-7. PMID: 28540606.

11. Stone JH, Zen Y, Deshpande V. 2012; IgG4-related disease. N Engl J Med. 366:539–51. DOI: 10.1056/NEJMra1104650. PMID: 22316447.

12. Corradi D, Maestri R, Palmisano A, Bosio S, Greco P, Manenti L, et al. 2007; Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int. 72:742–53. DOI: 10.1038/sj.ki.5002427. PMID: 17622270.

13. Vidarsson G, Dekkers G, Rispens T. 2014; IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 5:520. DOI: 10.3389/fimmu.2014.00520. PMID: 25368619. PMCID: PMC4202688.

14. Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. 2014; The clinical spectrum of IgG4-related disease. Autoimmun Rev. 13:1203–10. DOI: 10.1016/j.autrev.2014.08.013. PMID: 25151972.

15. Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. 2015; Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 90:927–39. DOI: 10.1016/j.mayocp.2015.03.020. PMID: 26141331.

16. Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. 2014; Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immuno-globulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 59:1954–63. DOI: 10.1002/hep.26977. PMID: 24375491. PMCID: PMC4489327.

17. Cronin CG, Lohan DG, Blake MA, Roche C, McCarthy P, Murphy JM. 2008; Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol. 191:423–31. DOI: 10.2214/AJR.07.3629. PMID: 18647912.

18. Ha YJ, Jung SJ, Lee KH, Lee SW, Lee SK, Park YB. 2011; Retroperitoneal fibrosis in 27 Korean patients: single center experience. J Korean Med Sci. 26:985–90. DOI: 10.3346/jkms.2011.26.8.985. PMID: 21860546. PMCID: PMC3154354.

19. Robins SA, Fischmann J. 1948; Hydronephrosis; a radiologic classification based on anatomical variations. Radiology. 50:632–8. DOI: 10.1148/50.5.632. PMID: 18917105.

20. Kim J, Park S, Hwang H, Kim JW, Cheon SH, Park S, et al. 2012; Comparison of surgical outcomes between dismembered pyeloplasty with or without ureteral stenting in children with ureteropelvic junction obstruction. Korean J Urol. 53:564–8. DOI: 10.4111/kju.2012.53.8.564. PMID: 22950002. PMCID: PMC3427842.

21. Soliman SA, Shokeir AA, Mosbah A, Abol-Enein H, Barakat N, Abou-Bieh E, et al. 2011; Recoverability of renal function after relief of chronic partial unilateral ureteric obstruction: the effect of an angiotensin-converting enzyme inhibitor (enalapril). Arab J Urol. 9:67–71. DOI: 10.1016/j.aju.2011.03.016. PMID: 26579271. PMCID: PMC4149048.

22. Fry AC, Singh S, Gunda SS, Boustead GB, Hanbury DC, McNicholas TA, et al. 2008; Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract. 108:c213–20. DOI: 10.1159/000119715. PMID: 18332635.

23. Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. 2011; Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 86:297–303. DOI: 10.4065/mcp.2010.0663. PMID: 21454732. PMCID: PMC3068889.

24. Yachoui R, Sehgal R, Carmichael B. 2016; Idiopathic retroperitoneal fibrosis: clinicopathologic features and outcome analysis. Clin Rheumatol. 35:401–7. DOI: 10.1007/s10067-015-3022-y. PMID: 26208444.

25. Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, et al. 2009; Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 33:1833–9. DOI: 10.1097/PAS.0b013e3181b72882. PMID: 19950407.

26. Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. 2011; Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med. 50:69–75. DOI: 10.2169/internalmedicine.50.4321. PMID: 21245628.

27. Culver EL, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC, et al. 2016; Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 111:733–43. DOI: 10.1038/ajg.2016.40. PMID: 27091321.

28. Pelkmans LG, Hendriksz TR, Westenend PJ, Vermeer HJ, van Bommel EFH. 2017; Elevated serum IgG4 levels in diagnosis and treatment response in patients with idiopathic retroperitoneal fibrosis. Clin Rheumatol. 36:903–12. DOI: 10.1007/s10067-017-3542-8. PMID: 28105551.

29. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. 2015; IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 67:2466–75. DOI: 10.1002/art.39205. PMID: 25988916. PMCID: PMC4621270.

30. van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. 2007; Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis. 49:615–25. DOI: 10.1053/j.ajkd.2007.02.268. PMID: 17472843.

31. van der Bilt FE, Hendriksz TR, van der Meijden WA, Brilman LG, van Bommel EF. 2016; Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J. 9:184–91. DOI: 10.1093/ckj/sfv148. PMID: 26985367. PMCID: PMC4792623.

32. Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. 2017; Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med. 12:287–99. DOI: 10.1007/s11739-016-1599-z. PMID: 28070877.

33. Ozawa M, Fujinaga Y, Asano J, Nakamura A, Watanabe T, Ito T, et al. 2017; Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study. Arthritis Res Ther. 19:223. DOI: 10.1186/s13075-017-1432-8. PMID: 28978347. PMCID: PMC5628426.